Denali Therapeutics Inc. (NASDAQ: DNLI) received U.S. Food and Drug Administration accelerated approval for AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE